Ein neuer US- Bio- Star!

Thema bewerten
Beiträge: 57
Zugriffe: 8.460 / Heute: 2
Vical kein aktueller Kurs verfügbar
 
Gruenspan:

Ein neuer US- Bio- Star!

 
11.03.03 13:09
Die aus San Diego stammende US- Bio- Firma "VICAL" WKN 886867 (VICL) hat den Start für einen Test ihres auf DNA basierenden Anthrax- Impstoff`s angekündigt.
In Zusammenarbeit mit der UNI OHIO  konnte VICAL breits beweisen, datt Hasen von dem Impfstoff gegen Anthrax immunisiert wurden.
Die Aktien der an der Nasdaq gelisteten Firma stiegen gestern gegen den Trend um mehr als 25 Prozent.


       Ein neuer US- Bio- Star! 966606
     

Ein neuer US- Bio- Star! 966606
>1x bewertet

Werbung

Entdecke die beliebtesten ETFs von Xtrackers

Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +52,09%
Xtrackers LevDAX Daily Swap UCITS ETF 1C
Perf. 12M: +38,37%
Xtrackers MSCI China UCITS ETF 1D
Perf. 12M: +37,83%
Xtrackers MSCI China UCITS ETF 1C
Perf. 12M: +37,65%
Xtrackers MSCI Singapore UCITS ETF 1C
Perf. 12M: +34,86%

first-henri:

Was meinst Du Grueni,

 
11.03.03 13:13
wenn die 2,5 halten eigentlich immer noch oder gerade dann ein klarer Kauf, oder ?
Bewerten
Gruenspan:

Auf jeden Fall einen

 
11.03.03 13:26
intensiveren Blick wert.

VICL

OPEN 3,19
HIGH 3,23
LOW  2,71
CLOSE 2,81
VOL 402.000
52- Range 2,12 - 10,14
LAST AFTER 2,82 - 900 Stücke

Das Hoch konnte gestern aufgrund des Gesamtmarktumfeld`s nicht gehalten werden.
Wäre schön, wenn VICL nochmal Anlauf nehmen würde.
Wenn sie demnächst dann den charttechnischen Weg von meinem alten Liebling "ALT" einschlagen würden, wäre datt ebenfalls not bad.
Die Gefahr von weiteren Gewinnmitnahmen besteht aber auch.
Beobachten und vielleicht reagieren.
Deshalb, Augen auf im Bio- Verkehr.



Ein neuer US- Bio- Star! 966628

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Pavian1:

Hi Gruenspan!

 
11.03.03 13:26
Glaube ab 3 Dollar wird es schwierig, die Widerstände haben gestern schon für Verkäufe gesorgt, denn intraday waren wir schon bei über 3.20 Dollar!

Grüße
Pavian
Bewerten
first-henri:

Die Amis lassen ihre Perlen nicht fallen,

 
11.03.03 13:29
höchstens hochschleichen, das würde mir reichen.

Greetz f-h
Bewerten
 
11.03.03 16:21
dabei zu $2,58.

Ein neuer US- Bio- Star! 966883
Bewerten
Pavian1:

Exakt auf Tagestief?

 
11.03.03 16:31
das hat sonst nur Star Ikone geschafft...  ;-)

Grüße
Bewerten
first-henri:

Nee, der Sieger schafft das auch

 
11.03.03 16:33
regelmäßig, der kauft sogar zu Bidkursen ein ;-)

Greetz f-h
Bewerten
Anzeige: Der Uran-Megatrend 2025

Aktie mit Knalleffekt: Uran-Geheimtipp zündet das nächste Bohr-Update
 
11.03.03 16:39
Vielleicht gibt es ja heute noch ein neues Tagestief, dann hab ich mal so richtig Pech gehabt.
Leichter Abgabedruck lastet jedenfalls auf VICL.
Ok, ma gucken!
Hab ja zur Zeit sonst nix weiter von drüben.

                                                 Gr.Gr.
Bewerten
first-henri:

Drück Dir die Daumen o. T.

 
11.03.03 16:42
Bewerten
Pichel:

gibts was Neues, überlege einzusteigen

 
14.03.03 12:33
wegen der Story
Bisschen korrigiert...

Gruß Pichel Ein neuer US- Bio- Star! 971187

Bewerten
Pichel:

geht wieder was? (nächster Schub?)

 
19.03.03 16:29

Gruß Pichel Ein neuer US- Bio- Star! 977189

Bewerten
Pavian1:

Schaut mal auf dieses heiße Teil!

 
26.03.03 10:51
Ein neuer US- Bio- Star! 984750chart.bigcharts.com/bc3/quickchart/...lf2=0&lf3=0&type=2&size" style="max-width:560px" >

FLML - werde mal sehen, ob ich was dazu finde...

Grüße
Pavian

PS Übrigens der erste Chart, den ich einfügen konnte!!!! YEP
Bewerten
Pavian1:

und läuft und läuft...

 
09.04.03 09:41
gestern wieder über 5%Plus!

Grüße
Pavian
Bewerten
 
03.07.03 09:09
Pavians FLML sind KLASSE gelaufen, VICL laufen jetzt!

Ein neuer US- Bio- Star! 1083310
Bewerten
 
03.07.03 18:00
Jetzt auch schöne Stücke in Deutschland gehandelt.
Selbst in Europa erhält VICAL jetzt von der zuständigen Behörde Krebsforschungspatente zugesprochen.
NEWS bei cbs. marketwatch.com

Ein neuer US- Bio- Star! 1084570
Bewerten
Pichel:

Wahnsinn und ich bin nich eingestiegen ;-(

 
03.07.03 18:50

Gruß Pichel Ein neuer US- Bio- Star! 1084651

Bewerten
Logo:

Liste der Aktivitäten (homepage 22.12.2004)

 
22.12.04 17:13
Product Pipeline
Product Area Project Target and Indication(s) Development Status (1) Development Rights
INFECTIOUS DISEASES
Infectious disease vaccines Plasmodium falciparum (malaria) Phase 1/2 Vical
" Cytomegalovirus Phase 1  Vical
" Bacillus anthracis (anthrax) Phase 1  Vical
" Ebola Phase 1  Vical/NIH
" West Nile Virus Preclinical Vical/NIH
" HIV - preventive Phase 1 Merck
" HIV - therapeutic Phase 1  Merck
" Hepatitis B - preventive Research Merck
" Hepatitis B - therapeutic Research Merck
" Hepatitis C - preventive Research Merck
CANCER
Immunotherapeutic vaccine High-dose Allovectin-7® for metastatic melanoma Phase 2  Vical
Interleukin-2/ electroporation Solid tumors  Preclinical Vical
Tumor-associated antigen therapeutic vaccines Unspecified cancer(2) Research Aventis Pasteur
" Unspecified cancer(2) Research Merck
CARDIOVASCULAR
Angiogenic growth factors VEGF-2 Phase 2  Corautus Genetics
" FGF-1 Phase 2  Gencell SAS
VETERINARY
Preventive vaccines  Various undisclosed (2) Research - Clinical Merial
 Undisclosed fish disease(2) Clinical Aqua Health  
Protective cancer vaccine Companion animal cancer(2) Clinical Merial

Wann sind Papiere gut: wenn (fast) keiner drüber redet. Zeit zum kaufen?????

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Kicky:

noch nicht

 
22.12.04 19:48
On December 16, 2004, we modified our equipment financing arrangement (the “Credit Facility”) with General Electric Capital Corporation (“GE Capital”) to provide for an additional leaseline of up to $8.5 million through October 31, 2005
We recorded revenues of $2.9 million for the three months ended September 30, 2004, compared with revenues of $4.9 million for the three months ended September 30, 2003. License and royalty revenue for both the three months ended September 30, 2004 and 2003, was $0.5 million .Our net loss was $4.9 million, or $0.21 per share, for the three months ended September 30, 2004, compared with a net loss of $3.6 million, or $0.18 per share, for the same period in the prior year.
www.pinksheets.com/quote/news.jsp?symbol=VICL
wenn da nicht ein Durchbruch gelingt...schau dir den Chart an,ungebrochener Abwärtstrend
da nützen dann auch die hochklingenden Pläne nicht,zumal den Auftrag über die Anthraximpfungen der 2.Generation jemand anderes bekommen hat und die Forschung zur 3.Generation noch nicht so weit ist
Bewerten
Logo:

noch nicht: dies war der entscheidende Fehler!

 
28.02.05 12:44
Es war ein guter Einstiegszeitpunkt.  Die Aktie hat die Trendwende geschafft !!
Bewerten
_bbb_:

Swine FLU ?

 
27.04.09 10:41
VETERINARY APPLICATIONSPrior to development for human therapy, our DNA delivery technologies were extensively tested in animals. Research scientists have published numerous papers detailing favorable results in many species and covering a broad range of disease indications. Animal health encompasses two distinct market segments: livestock, or animals bred and raised for food or other products, and companion animals, or pets. Through our collaborative partnerships with Merial and Aqua Health, there have been approvals within each of these market segments for vaccines utilizing our DNA delivery technology.
Bewerten
_bbb_:

Chart

 
27.04.09 11:17

Ein neuer US- Bio- Star! 5749272www.finviz.com/chart.ashx?t=VICL&ta=1&p=d&s=l" style="max-width:560px" />

Bewerten
_bbb_:

link mit noch mehr Info

 
27.04.09 11:18
Bewerten
_bbb_:

Schnell

 
27.04.09 14:09
Alle an Board !!!!!
Bewerten
_bbb_:

NEW !

 
07.05.09 09:27
Vical and U.S. Navy to Expedite Development of H1N1 Pandemic Influenza (Swine Flu) Vaccine


SAN DIEGO, May 6, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company has entered into a Cooperative Research and Development Agreement (CRADA(i)) with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the U.S. Navy, for the expedited development of a vaccine against the potentially pandemic H1N1 strain of influenza virus. The goal of the collaborative development program is to rapidly advance a Vaxfectin(r)-formulated H1N1 DNA vaccine into clinical testing as quickly as possible. Vical would be responsible for securing regulatory approval of the vaccine for use in the United States and other countries.

"The rapid spread and potential impact of H1N1 influenza have led to a U.S. government declaration of a health care emergency and a World Health Organization (WHO) declaration of a Phase 5 pandemic alert," said Vijay B. Samant, Vical's President and Chief Executive Officer. "We believe our technology is particularly well-suited to emerging infectious diseases like H1N1 influenza for which conventional vaccine technologies are too slow in both development and manufacturing. The successful completion of Phase 1 human trials of our Vaxfectin(r)-formulated DNA vaccines against H5N1 pandemic influenza last year positions us to pursue rapid development of a vaccine to address the threat of an influenza pandemic. We are pleased to collaborate with the U.S. Navy on this H1N1 vaccine development mission."

About Vical

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
_bbb_:

News !

 
21.05.09 13:17
VICL News !
Vical Advances H1N1 Pandemic Influenza (Swine Flu) Vaccine
ir.vical.com/releasedetail.cfm?ReleaseID=385438
Bewerten
_bbb_:

wowow

 
21.05.09 16:34
:-)

+30
Bewerten
_bbb_:

...

 
21.05.09 17:34
Latest Shares Outstanding 40.4 mil
Bewerten
_bbb_:

2.95$ nhod

 
21.05.09 17:51
Gooooo
Bewerten
_bbb_:

Mittagspause ist ladezeit

 
21.05.09 18:22
Hopp...alles unter 2 € ist billig !!!!
Bewerten
_bbb_:

Chart...

 
21.05.09 18:38
(Verkleinert auf 71%) vergrößern
Ein neuer US- Bio- Star! 234293
Bewerten
_bbb_:

gap closed ?

 
21.05.09 23:25
hm :-)
Bewerten
_bbb_:

UK's attempts to stop swine flu called flawed

 
22.05.09 11:54
Bewerten
_bbb_:

More City Schools Closed by Flu

 
22.05.09 11:56
Bewerten
_bbb_:

Vical to Raise $15.4 Million in Registered Direct

 
22.05.09 15:09
news.moneycentral.msn.com/provider/...=20090522&id=9929667

Vical to Raise $15.4 Million in Registered Direct Offering

Friday , May 22, 2009 08:30ET


SAN DIEGO, May 22, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has received commitments from two institutional investors, including Federated Kaufmann Fund, to purchase approximately $15.4 million of securities in a registered direct offering. Vical expects to receive net proceeds of approximately $14.6 million after deducting placement agent fees and other offering expenses. Under the terms of a Securities Purchase Agreement, Vical will sell an aggregate of 6,666,667 shares of its common stock and options to purchase up to 3,333,333 additional shares of its common stock. Each unit, consisting of one share of common stock and an option to purchase approximately one-half of a share of common stock, will be sold for a purchase price of $2.3125. The options to purchase additional shares will be exercisable six months after issuance at $2.25 per share and will expire 90 days from the date they are first exercisable. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used in the further development of Vical's ongoing programs, as well as for other general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq:RODM) acted as the placement agent for the transaction.
Bewerten
_bbb_:

Ceo Interview 2008

 
24.05.09 13:05
Bewerten
_bbb_:

hm...

 
24.05.09 13:27
Bewerten
_bbb_:

2$ Doppelboden ?

 
24.05.09 13:39

finviz.com/quote.ashx?t=VICL&ta=1&p=d

 

Ein neuer US- Bio- Star! 5878302finviz.com/chart.ashx?t=VICL&ta=1&p=d&s=l" style="max-width:560px" />

Bewerten
_bbb_:

hmmm....

 
24.05.09 13:42

Ein neuer US- Bio- Star! 5878307stockcharts.com/def/servlet/...2!a][d][f1!3!!!4!20]&pnf=y" style="max-width:560px" />

Bewerten
_bbb_:

Which Small Biotech Firms Could Reap Benefits From

 
24.05.09 14:03
Which Small Biotech Firms Could Reap Benefits From Government's Flu Vaccine Initiative?

biomedreports.com/articles/most-popular/...fluenza-a-h1n1.html
Bewerten
_bbb_:

nochmal nachgelegt...

 
03.06.09 22:20
(Verkleinert auf 71%) vergrößern
Ein neuer US- Bio- Star! 236672
Bewerten
_bbb_:

Intraday

 
03.06.09 22:22
(Verkleinert auf 71%) vergrößern
Ein neuer US- Bio- Star! 236673
Bewerten
_bbb_:

aha...

 
03.06.09 23:26
Posted by: surf1944    Date: Wednesday, June 03, 2009 5:22:40 PM  
In reply to: None  Post # of 113    

6:31AM Vical announces issuance of U.S. patent for universal influenza vaccine approach (VICL) 2.20 : Co announces the issuance of U.S. Patent No. 7,537,768 covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as well as emerging pandemic strains of influenza viruses.
Bewerten
_bbb_:

Strong Buy...

 
04.06.09 13:32
Bewerten
Nassie:

Na gut

 
04.06.09 13:44
wenn du das sagst, dann habe ich mal eine Order plaziert.
Bewerten
Nassie:

Gute Übersicht

 
06.06.09 13:31
Bewerten
_bbb_:

:-)

 
06.06.09 17:21
Bewerten
>1x bewertet
_bbb_:

...

 
11.06.09 23:34
Schweinegrippe.....
WHO / Stufe6 Pandemie....
Bewerten
Nassie:

Die Fonds kaufen sich ein

 
13.06.09 01:27
Bewerten
Nassie:

News

 
18.06.09 14:30
Vical Advances RapidResponse DNA Vaccine Platform Under $6 Mln Grant From NIH - Quick Facts



(RTTNews) - Vical Inc. (VICL) announced that it has completed second-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine manufacturing process with the potential to produce several million doses of vaccines in a matter of days.

The RapidResponse system is designed to allow extremely rapid and large-scale production of DNA vaccines with low capital requirements. It is ideally suited to enable an immediate response against emerging diseases affecting large populations, such as H1N1 or H5N1 pandemic influenza or severe acute respiratory syndrome (SARS).

The company is proceeding with the development of the RapidResponse platform under the third year of grant funding awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health or NIH.

For comments and feedback: contact editorial@rttnews.com
Bewerten
_bbb_:

...

 
18.06.09 15:25
DATE 1-Vical advances development of DNA vaccine platform
Thu Jun 18, 2009 7:35am EDT  Email | Print | Share| Reprints | Single Page[-] Text [+]

Market News
Stock futures flat before data, Geithner in focus
Oil dips below $71 on firm dollar, weak equities
Global stocks near three-week low
More Business & Investing News... Featured Broker sponsored link
* Says meets second-year milestones

* Platform allows large-scale production of DNA vaccines

June 18 (Reuters) - Vical Inc (VICL.O) said it is taking the development of its DNA vaccine manufacturing process into the third year, under a $6 million grant from the National Institutes of Health, after meeting its second-year milestones.

The RapidResponse system significantly reduces the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak, the company said in a statement.

Vical said the system is ideally suited against diseases like H1N1 or H5N1 pandemic influenza or severe acute respiratory syndrome (SARS).

For the alerts, please double-click [ID:nWNAB0913] (Reporting by Shailesh Kuber in Bangalore; Editing by Deepak Kannan)
Bewerten
Nassie:

Gute Nachrichten

 
11.01.10 14:44
und vorbörslich deutlich im PLus.
Bewerten
Nassie:

News

 
12.01.10 14:04
Vical Licensee AnGes MG Inks Deal With FDA For Phase 3 Trial Of Collategene Angiogenesis Product - Quick Facts



(RTTNews) - Tuesday, Vical Inc. (VICL) said its licensee, AnGes MG, Inc., reported approval by the U.S. Food and Drug Administration or FDA of the Special Protocol Assessment or SPA agreement for a Phase 3 clinical trial of its Collategene angiogenesis product for patients with advanced peripheral arterial disease or PAD. The study will be multinational, randomized and placebo-controlled with a target population of 560 patients.

PAD is a major health problem caused mostly by atherosclerotic narrowing of lower limb arteries that significantly reduces the blood flow to the limbs. Early symptoms of PAD include transient pain in the legs upon walking, a condition called intermittent claudication, which is caused by ischemia.

The company stated that the phase 3 trial will enroll no option as well as poor option patients with chronic and severe ischemia of the lower limb or Critical Limb Ischemia. No option patients are those unable to get an endovascular intervention or surgical bypass procedure due to inflow, conduit or outflow reasons or due to a severe and irreversible co-morbidity where surgery is contraindicated.

For comments and feedback: contact editorial@rttnews.com
Bewerten
Nassie:

Insiderkäufe

 
13.01.10 10:37
3 Form 4 Filings in dieser Woche.
Bewerten
Nassie:

News

 
26.01.10 14:13
Vical Inc. Updates Vaccine Development Programs For CMV And Pandemic Influenza - Quick Facts



(RTTNews) - Tuesday, Vical Inc. (VICL) said it will present an overview of its DNA vaccine and adjuvant technologies and an update on its clinical-stage vaccine development programs at the Phacilitate Vaccine Forum. Alain Rolland, Vical's Executive Vice President of Product Development, is scheduled to present on Wednesday, January 27, at 12:55 p.m.

Rolland's presentation, "Delivery systems and adjuvants for DNA-based vaccines: Development of prophylactic and therapeutic vaccines," highlights the interim Phase 2 clinical data for the company's TransVax therapeutic cytomegalovirus or CMV vaccine for transplant recipients, and the development of its Vaxfectin-adjuvanted H5N1 and H1N1 pandemic influenza DNA vaccines.

For comments and feedback: contact editorial@rttnews.com
Bewerten
Nassie:

News

 
28.01.10 14:08
Vical Completes Enrollment in Allovectin-7(r) Phase 3 Trial for Metastatic Melanoma



SAN DIEGO, Jan. 28, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company has completed enrollment of the planned 375 subjects in its multinational Phase 3 trial of Allovectin-7(R) in patients with metastatic melanoma. Allovectin-7(R) is a novel gene-based immunotherapeutic with a unique mechanism of action that is fundamentally different from currently approved treatments, and has the potential to be the first new primary treatment approved for metastatic melanoma in nearly 20 years.

"We are pleased to complete enrollment in this pivotal Phase 3 Allovectin-7(R) trial," said Vijay Samant, Vical's President and Chief Executive Officer. "We focused our recruitment efforts in North America, major European countries, Israel and Brazil, paving the path toward approvals in these key melanoma markets. Through the Special Protocol Assessment (SPA) process with the FDA, we designed our trial to demonstrate the advantages of our approach and improve the probability of success in achieving our primary endpoint of overall response rate."

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Es gibt keine neuen Beiträge.
 Ich: 

Seite: Übersicht Alle 1 2 3

Börsen-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Vical Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
4 935 Vical - Der Neuanfang silberfisch silberfisch 25.04.21 02:13
2 687 Vical - mit Allovectin7 zum Milliardenkonzern silberfisch Sunatnight 15.08.13 08:17
4 726 Vical könnte zum echten Homerun werden hoomer trader2011 19.05.12 13:40
  1 Vical benni1 82lukas 27.12.10 09:40
  56 Ein neuer US- Bio- Star! Gruenspan Nassie 28.01.10 14:08